Yayın:
The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib

Sadeleştirilmiş öğe sayfası
dc.contributor.authorSelin Engür
dc.contributor.authorEngür, Selin
dc.contributor.authorMiriş Dikmen
dc.contributor.authorDikmen, Miriş
dc.contributor.orcid0000-0003-1534-8117
dc.contributor.orcid0009-0000-1090-0166
dc.date.accessioned2025-11-13T10:01:13Z
dc.date.issued2017-03-22
dc.identifier.doi10.1080/17843286.2017.1302623
dc.identifier.endpage398
dc.identifier.issn1784-3286
dc.identifier.issue6
dc.identifier.openalexW2600833804
dc.identifier.pubmed28327055
dc.identifier.scopus2-s2.0-85015825177
dc.identifier.startpage391
dc.identifier.urihttps://hdl.handle.net/11421/2918
dc.identifier.urihttps://doi.org/10.1080/17843286.2017.1302623
dc.identifier.volume72
dc.identifier.wos000415688800003
dc.language.isoen
dc.relation.ispartofActa Clinica Belgica
dc.rightsrestrictedAccess
dc.subjectBortezomib
dc.subjectIxazomib
dc.subjectProteasome inhibitor
dc.subjectApoptosis
dc.subjectMedicine
dc.subjectPharmacology
dc.subjectCancer research
dc.subjectProteasome
dc.subjectInternal medicine
dc.subjectMultiple myeloma
dc.subjectBiology
dc.subjectBiochemistry
dc.subjectCarfilzomib
dc.subject.sdg3
dc.titleThe evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5021293880
local.authorid.openalexA5042645402

Dosyalar

Koleksiyonlar

Publications